HLSC 2P27 Lecture Notes - Lecture 7: Belatacept, Cancer Screening, Kidney Transplantation

• School: Brock University
• Department: Health Sciences
• Course: HLSC 2P27
• Professor: Carolynn Pietrangeli

Document Summary

Rct: quantitative trial, the efficacy and safety of treatment is evaluated in groups of subjects followed prospectively, patients are randomly assigned, treatment group, follow up, control group, follow up, compare results. What strengths are associated with randomization: avoidance of, selection bias, subjects are assigned to groups independently of the investigator, confounding. Hlsc 2p27: random assignment of subjects to each study arm balances the confounders between/among groups, balance of unknown prognostic factors between treatment groups, nullifying their effect on outcome. When is randomization inappropriate: harmful exposure, ethics, cancer screening, rare event; long delay, case-control, cohort more appropriate, financial constraints, expectation of low adherence, high drop out. What is blinding: keeping trial participants, investigators, data collectors and processors unaware of the assigned intervention of each study subject, purpose, to prevent bias/influence in the conduction of the trial, interpretation of results and differential treatment of subjects.